Trial Profile
A pivotal phase III trial to investigate Qbeco in patients with Crohn's disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 28 Dec 2015
Price :
$35
*
At a glance
- Drugs QBECO (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- 28 Dec 2015 New trial record
- 23 Dec 2015 This trial is expected to begin in early 2017, according to a Qu Biologics media release.